Covid-19 Research

Research Highlights

Development of a Novel Anti-SARS-CoV-2 Antiviral: Effective Inhibitory Activity of Brilacidin

Journal of Biomedical Research & Environmental Sciences article abstract with citation details, DOI, publication dates, subject areas, full text links, and references.

View DOI Submit Manuscript

Article Details

Publication record, authors, dates, abstract, and full text access.

Open Access
Article Type Research Highlights
Subject Biology Group
OCLC 9575253882
Zelia Nelly Ndoutoume, Arnaud John Kombe Kombe* and Fleury Augustin Nsole Biteghe
Issue: Volume3-Issue6
Pages: 726-728
Received: 2022-06-27
Accepted: 2022-06-29
Published: 2022-06-30

Abstract

The race to develop effective therapeutics/therapies against SARS-CoV-2 infections and COVID-19 is ongoing as the pandemic is still far from being controlled. Recently, three groups of scientists including Bakovic, et al. [1], Xu, et al. [2]and Hu, et al. [3] respectively, reported a promising and highly attractive antiviral activity of a new drug, named brilacidin, against SARS-CoV-2 infections.

FullText HTML FullText PDF DOI: 10.37871/jbres1504 Crossmark

Certificate of Publication

Certificate of Publication

Copyright

© 2022 Ndoutoume ZN, et al. Distributed under Creative Commons CC-BY 4.0 Creative CommonsAttribution

How to cite this article

Ndoutoume ZN, Kombe Kombe AJ, Nsole Biteghe FA. Development of a Novel Anti-SARS-CoV-2 Antiviral: Effective Inhibitory Activity of Brilacidin. J Biomed Res Environ Sci. 2022 June 30; 3(6): 726-726. doi: 10.37871/jbres1504, Article ID: JBRES1504, Available at: https://www.jelsciences.com/articles/jbres1504.pdf

Subject area(s)

VaccinesAntivirologyVirology

References

  1. Bakovic A, Risner K, Bhalla N, Alem F, Chang TL, Weston WK, Harness JA, Narayanan A. Brilacidin demonstrates inhibition of SARS-CoV-2 in cell culture. Viruses. 2021 Feb 9;13(2):271. doi: 10.3390/v13020271. PMID: 33572467; PMCID: PMC7916214.
  2. Xu C, Wang A, Honnen W, Pinter A, Weston WK, Harness JA, Narayanan A, Chang TL. Brilacidin, a non-peptide defensin-mimetic molecule, inhibits SARS-CoV-2 infection by blocking viral entry. EC Microbiol. 2022 Apr;18(4):1-12. Epub 2022 Mar 8. PMID: 35695877; PMCID: PMC9186380.
  3. Hu Y, Jo H, DeGrado WF, Wang J. Brilacidin, a COVID-19 drug candidate, demonstrates broad-spectrum antiviral activity against human coronaviruses OC43, 229E, and NL63 through targeting both the virus and the host cell. J Med Virol. 2022 May;94(5):2188-2200. doi: 10.1002/jmv.27616. Epub 2022 Feb 2. PMID: 35080027; PMCID: PMC8930451.
  4. Shang Y, Li H, Zhang R. Effects of pandemic outbreak on economies: Evidence from business history context. Front Public Health. 2021 Mar 12;9:632043. doi: 10.3389/fpubh.2021.632043. PMID: 33777885; PMCID: PMC7994505.
  5. Cucinotta D, Vanelli M. WHO declares COVID-19 a pandemic. Acta Biomed. 2020 Mar 19;91(1):157-160. doi: 10.23750/abm.v91i1.9397. PMID: 32191675; PMCID: PMC7569573.
  6. Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, Zhao X, Huang B, Shi W, Lu R, Niu P, Zhan F, Ma X, Wang D, Xu W, Wu G, Gao GF, Tan W; China Novel Coronavirus Investigating and Research Team. A novel coronavirus from patients with pneumonia in china, 2019. N Engl J Med. 2020 Feb 20;382(8):727-733. doi: 10.1056/NEJMoa2001017. Epub 2020 Jan 24. PMID: 31978945; PMCID: PMC7092803.
  7. Czeisler ME, Howard ME, Robbins R, Barger LK, Facer, Rajaratnam SMW, Czeisler CA. Early public adherence with and support for stay-at-home COVID-19 mitigation strategies despite adverse life impact: a transnational cross-sectional survey study in the United States and Australia. BMC Public Health. 2021;21(1):503.
  8. Duan K, Liu B, Li C, Zhang H, Yu T, Qu J, Zhou M, Chen L, Meng S, Hu Y, Peng C, Yuan M, Huang J, Wang Z, Yu J, Gao X, Wang D, Yu X, Li L, Zhang J, Wu X, Li B, Xu Y, Chen W, Peng Y, Hu Y, Lin L, Liu X, Huang S, Zhou Z, Zhang L, Wang Y, Zhang Z, Deng K, Xia Z, Gong Q, Zhang W, Zheng X, Liu Y, Yang H, Zhou D, Yu D, Hou J, Shi Z, Chen S, Chen Z, Zhang X, Yang X. Effectiveness of convalescent plasma therapy in severe COVID-19 patients. Proc Natl Acad Sci U S A. 2020 Apr 28;117(17):9490-9496. doi: 10.1073/pnas.2004168117. Epub 2020 Apr 6. PMID: 32253318; PMCID: PMC7196837.
  9. Rodrigues L, Bento Cunha R, Vassilevskaia T, Viveiros M, Cunha C. Drug repurposing for COVID-19: A review and a novel strategy to identify new targets and potential drug candidates. Molecules. 2022 Apr 23;27(9):2723. doi: 10.3390/molecules27092723. PMID: 35566073; PMCID: PMC9099573.
  10. Mengist HM, Kombe Kombe AJ, Mekonnen D, Abebaw A, Getachew M, Jin T. Mutations of SARS-CoV-2 spike protein: Implications on immune evasion and vaccine-induced immunity. Semin Immunol. 2021 Jun;55:101533. doi: 10.1016/j.smim.2021.101533. Epub 2021 Nov 20. PMID: 34836774; PMCID: PMC8604694.
  11. Zhang H, Deng S, Ren L, Zheng P, Hu X, Jin T, Tan X. Profiling CD8+ T cell epitopes of COVID-19 convalescents reveals reduced cellular immune responses to SARS-CoV-2 variants. Cell Rep. 2021 Sep 14;36(11):109708. doi: 10.1016/j.celrep.2021.109708. Epub 2021 Aug 27. PMID: 34506741; PMCID: PMC8390359.
  12. Mohammad Zadeh N, Mashinchi Asl NS, Forouharnejad K, Ghadimi K, Parsa S, Mohammadi S, Omidi A. Mechanism and adverse effects of COVID-19 drugs: A basic review. Int J Physiol Pathophysiol Pharmacol. 2021 Aug 15;13(4):102-109. PMID: 34540130; PMCID: PMC8446775.
  13. Aygün İ, Kaya M, Alhajj R. Identifying side effects of commonly used drugs in the treatment of Covid 19. Sci Rep. 2020 Dec 9;10(1):21508. doi: 10.1038/s41598-020-78697-1. PMID: 33299085; PMCID: PMC7725770.
  14. Zeng W, Liu G, Ma H, Zhao D, Yang Y, Liu M, Mohammed A, Zhao C, Yang Y, Xie J, Ding C, Ma X, Weng J, Gao Y, He H, Jin T. Biochemical characterization of SARS-CoV-2 nucleocapsid protein. Biochem Biophys Res Commun. 2020 Jun 30;527(3):618-623. doi: 10.1016/j.bbrc.2020.04.136. Epub 2020 Apr 30. Erratum in: Biochem Biophys Res Commun. 2022 Jul 23;614:225. PMID: 32416961; PMCID: PMC7190499.
Publish with JBRES — Peer-reviewed, multidisciplinary Open Access with rapid review, DOI, and global visibility.
Double-Blind CrossRef DOI Discoverable
Submit Manuscript Membership